Clinical Trials for PCS499
PCS499 is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline (PTX or Trental®). PCS499 is being developed for the treatment of Necrobiosis Lipoidica (NL), a chronic, disfiguring condition affecting the skin and the tissue under the skin typically on the lower extremities.
PCS499 and its metabolites affect several biological pathways, several of which contribute to the pathophysiology associated with NL. Therefore, PCS499 may provide a novel treatment solution for NL, a condition for which there are currently no FDA-approved treatments.
PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
This is a randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of PCS499 as compared to placebo for the treatment of ulcerations of patients with necrobiosis lipoidica (NL) and will inform the design of future studies.View Clinical Trial
Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors
This study is an open-label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.View Clinical Trial
For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
The safety and efficacy of the investigational use of this product have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.